Nucl Med Biol
-
Publication Venue For
- Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.. 100-101:24-35. 2021
- Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.. 94-95:67-80. 2021
- Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters.. 80-81:45-56. 2020
- A trithiol bifunctional chelate for 72,77As: A matched pair theranostic complex with high in vivo stability.. 61:1-10. 2018
- Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.. 56:10-20. 2018
- Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.. 62-63:18-30. 2018
- Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles.. 46:43-49. 2017
- Trithiols and their arsenic compounds for potential use in diagnostic and therapeutic radiopharmaceuticals.. 43:288-295. 2016
- Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.. 42:673-684. 2015
- Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.. 42:439-445. 2015
- D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.. 42:19-27. 2015
- Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.. 41:710-715. 2014
- Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic.. 41:441-449. 2014
- N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.. 41:802-812. 2014
- Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.. 40:52-59. 2013
- Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET.. 39:1266-1274. 2012
- A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).. 39:1012-1018. 2012
- Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.. 39:23-34. 2012
- Radioiodinated O(6)-Benzylguanine derivatives containing an azido function.. 38:77-92. 2011
- Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.. 37:741-750. 2010
- Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.. 37:785-794. 2010
- Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia.. 37:557-564. 2010
- Targeting aldehyde dehydrogenase: a potential approach for cell labeling.. 36:919-929. 2009
- Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.. 36:671-680. 2009
- Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.. 36:659-669. 2009